Petros Pharmaceuticals, Inc. [Rocket]

Overview

Petros Pharmaceuticals, Inc.

Add to portfolio

Recent News + Filings (All items)

Date Filed	Type	Description
10/02/2023	8-K	Quarterly results
08/25/2023	DEF 14A	Form DEF 14A - Other definitive proxy statements:
08/15/2023	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
08/15/2023	PRE 14A	Form PRE 14A - Other preliminary proxy statements:
08/14/2023	10-Q	Quarterly Report for the period ended June 30, 2023
08/11/2023	S-3	Form S-3 - Registration statement under Securities Act of 1933:
07/21/2023	D	Form D - Notice of Exempt Offering of Securities:

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19
Revenues	6.0	7.8	9.6	15.6
Revenue growth	-23.3%	-18.3%	-38.6%
Cost of goods sold	2.3	1.6	4.0	7.4
Gross profit	3.7	6.2	5.5	8.2
Gross margin	61.8%	79.5%	57.7%	52.3%
Selling, general and administrative	12.2	15.6	15.7	19.7
Research and development	1.7	1.8	0.5
EBITA	-6.9	-11.2	-17.3	-16.9
EBITA margin	-114.6%	-143.1%	-180.8%	-108.3%
Amortization of intangibles	5.6	6.9
EBIT	-12.5	-18.0	-17.3	-16.9
EBIT margin	-207.9%	-231.1%	-180.8%	-108.3%
Pre-tax income	-20.0	-9.0	-22.0	-33.2
Income taxes	0.0	0.0	-1.4	-0.6
Tax rate	0.0%	0.0%	6.5%	1.9%
Net income	-20.0	-9.0	-20.6	-32.5
Net margin	-334.4%	-115.0%	-215.3%	-208.7%

Diluted EPS	($9.68)	($8.25)	($3.85)	($13.22)
Shares outstanding (diluted)	2.1	1.1	5.3	2.5

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.